1
Clinical Trials associated with 8 HLA-A2 restricted peptides and Montanide ISA-51(Ludwig Institute for Cancer Research)A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1.
This cancer vaccine research study involves the injection of the NY-ESO-1b peptide along with 2 other agents to help stimulate the immune system. Peptides are small fragments of protein. NY- ESO-1 peptides are normally found in the testis and the placenta. They have also been found on various types of cancer cells. The purpose is to stimulate the immune system to react against the peptides that are found on cancer cells.
100 Clinical Results associated with 8 HLA-A2 restricted peptides and Montanide ISA-51(Ludwig Institute for Cancer Research)
100 Translational Medicine associated with 8 HLA-A2 restricted peptides and Montanide ISA-51(Ludwig Institute for Cancer Research)
100 Patents (Medical) associated with 8 HLA-A2 restricted peptides and Montanide ISA-51(Ludwig Institute for Cancer Research)
100 Deals associated with 8 HLA-A2 restricted peptides and Montanide ISA-51(Ludwig Institute for Cancer Research)